Exicure Presents Positive Biomarker Results from Clinical Trial of XCUR17
October 16 2019 - 7:00AM
Business Wire
-- XCUR17 clinical results announced in
presentation at the 15th Annual Meeting of the Oligonucleotide
Therapeutics Society in Munich --
-- Clinical results presented show decrease in
the levels of psoriasis and inflammation markers --
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced that its chief executive officer, Dr. David
Giljohann, presented clinical data from the company’s drug
candidate XCUR17 in psoriasis today during the Oligonucleotides
Clinical Studies session at the 15th Annual Meeting of the
Oligonucleotide Therapeutics Society (OTS) in Munich.
The presentation titled, “Clinical Results from XCUR17, a
Topically Applied Antisense Spherical Nucleic Acid in Patients with
Psoriasis,” highlighted work by Dr. James Krueger at The
Rockefeller University, in collaboration with Exicure, to examine
the effects of XCUR17 in Phase 1 patient samples. In that study,
all patients received daily applications of three strengths of
XCUR17 gel and vehicle gel to different areas of psoriatic skin for
25 days. Biopsies were collected from the application areas after
the 25 day treatment period as well as from lesional and
nonlesional skin at baseline.
Clinical findings, correlated with psoriasis-related markers and
histological changes from biopsies provided by the patients (n =
21), showed that XCUR17 treatment:
- Resulted in a decrease in the levels of psoriasis and
inflammation markers downstream of XCUR17's target, IL-17RA
- Produced a statistically significant reduction in keratin 16
expression, a key marker of psoriasis (p=0.002)
- Resulted in reductions in the major inflammatory markers beta
defensin 4A, interleukin 19, and interleukin 36A versus psoriatic
skin at baseline
- Revealed clinical improvements that matched reductions in
keratin 16 protein and epidermal thickness
Today’s clinical update follows a December 17, 2018 company
announcement of top-line results from a Phase 1 trial evaluating
XCUR17 in patients with mild-to-moderate chronic plaque psoriasis.
In that trial, the highest strength XCUR17 gel showed a
statistically significant improvement in psoriasis symptoms. Such
findings from the Phase 1 trial suggest that SNA-based drugs, such
as XCUR17, may address clinical symptoms in patients with
inflammatory diseases such as psoriasis.
Dr. Giljohann’s presentation is available in the Investors &
News section of Exicure’s website.
About XCUR17
Exicure’s drug candidate, XCUR17, is an SNA targeted to mRNA
encoding interleukin 17 receptor alpha, or IL-17RA which is a key
protein that propagates the inflammation underlying psoriasis. In
preclinical studies, XCUR17 inhibited IL-17RA expression in human
skin and in psoriatic mouse models.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for immuno-oncology, inflammatory diseases
and genetic disorders based on our proprietary Spherical Nucleic
Acid, or SNA technology. Exicure believes that its proprietary SNA
architecture has distinct chemical and biological properties that
may provide advantages over other nucleic acid therapeutics and may
have therapeutic potential to target diseases not typically
addressed with other nucleic acid therapeutics. Exicure's lead
program is in a Phase 1b/2 trial in patients with advanced solid
tumors. Exicure is based outside of Chicago, IL and in Cambridge,
MA. www.exicuretx.com
Forward Looking Statements This press release contains
forward-looking statements (including within the meaning of Section
21E of the United States Securities Exchange Act of 1934, as
amended, and Section 27A of the United States Securities Act of
1933, as amended) concerning the Company, the Company’s technology,
potential therapies and other matters. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“believe,” “intend,” “look forward,” and other similar expressions
among others. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: unexpected costs, charges or
expenses that reduce cash runway; that many drug candidates that
have completed Phase 1 trials do not become approved drugs on a
timely or cost effective basis or at all; possible safety and
efficacy concerns; regulatory developments; and the ability of
Exicure to protect its intellectual property rights. XCUR17 is in
early stage of clinical development, and the process by which
XCUR17 could potentially lead to an approved therapeutic is long
and subject to significant risks, unknowns, and uncertainties.
Risks facing the Company and its programs are set forth in the
Company’s filings with the SEC. Except as required by applicable
law, the Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191016005268/en/
MacDougall Karen Sharma 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024